Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Total Liabilities : ¥1,504.0 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Suzhou Zelgen Biopharmaceuticals Co Total Liabilities?

Suzhou Zelgen Biopharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥1,504.0 Mil.

Suzhou Zelgen Biopharmaceuticals Co's quarterly Total Liabilities increased from Sep. 2023 (¥1,109.63 Mil) to Dec. 2023 (¥1,242.37 Mil) and increased from Dec. 2023 (¥1,242.37 Mil) to Mar. 2024 (¥1,504.04 Mil).

Suzhou Zelgen Biopharmaceuticals Co's annual Total Liabilities increased from Dec. 2021 (¥492.88 Mil) to Dec. 2022 (¥880.83 Mil) and increased from Dec. 2022 (¥880.83 Mil) to Dec. 2023 (¥1,242.37 Mil).

Suzhou Zelgen Biopharmaceuticals Co Total Liabilities Historical Data

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suzhou Zelgen Biopharmaceuticals Co Total Liabilities Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

246.52

283.51

492.88

880.83

1,242.37

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															930.57	1,030.38	1,109.63	1,242.37	1,504.04

Suzhou Zelgen Biopharmaceuticals Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Suzhou Zelgen Biopharmaceuticals Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1135.181	+	(29.456	+	77.733
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,242.4

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2887.207	-	1644.837
	=	1,242.4

Suzhou Zelgen Biopharmaceuticals Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1208.19	+	(31.526	+	264.32
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,504.0

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3104.748	-	1600.712
	=	1,504.0

Suzhou Zelgen Biopharmaceuticals Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Suzhou Zelgen Biopharmaceuticals Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Suzhou Zelgen Biopharmaceuticals Co Ltd (SHSE:688266) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN

Website

http://www.zelgen.com

Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.

Executives

Zhang Bin	Core technical personnel
Huang Gang	senior management
Lv Bin Hua	Directors, senior managers, core technical personn
Lu Hui Ping	Directors, senior managers
Gao Qing Ping	senior management
Wu Ji Sheng	Directors, senior managers, core technical personn
Zhang Jun Li	senior management
Wu Li Qing	Core technical personnel
	Core technical personnel
Sheng Ze Lin	Directors, senior managers, core technical personn

Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Headlines

No Headlines